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Hemoglobin Variability and
Hyporesponsiveness: Much Ado About
Something or Nothing?
Jerry Yee, Gerard Zasuwa, Stanley Frinak, and Anatole Besarab
Hemoglobin (Hb) variability is considered a discrete clinical entity that when present may presage poor
clinical outcomes. However, Hb variability is an intrinsic property of biological systems and is present in
all patients, those with and without the anemia of chronic kidney disease. Taken together, variability
actually represents the integration of multiple influences at multiple levels in the life of a red cell,
namely the summation of positive and negative influences on erythropoiesis. Thus, Hb variability
may be interpreted as a mathematic function of time and is the result of a host of influences including
definition of the normal Hb range, native erythron responsiveness/hyporesponsiveness, temporal
changes in endogenous and exogenous erythropoiesis-stimulating agent (ESA) levels, the algorithms
used to dose ESAs and their duration of action, the presence of biologically available iron, red cell turnover, and recyclable and non-recyclable blood loss and gain. When viewed within this construct of
matrixed determinants, the source of hemoglobin variability is more readily identified. When variability
is present but the etiology is not easily discerned, erythropoietic hyporesponsivess must be considered
and evaluated. Finally, integration of all of these concepts is possible within the context of an anemia
management protocol.
Q 2009 by the National Kidney Foundation, Inc. All rights reserved.
Index Words: Anemia; Chronic kidney disease; Variability; Sensitivity; Hyporesponsiveness; Erythropoiesis-stimulating agent; Iron deficiency

V

ariability is defined as the degree by
which repetitive measures of a tested parameter vary.1,2 The case is no different for
hemoglobin (Hb). The range of any given
Hb level is bounded by ascertainment of the
parameter within the general population
and the coefficient of variation inherent to
the measuring device, the latter yielding the
coefficient of difference of the variable.2 Variability can be construed within the context of
a single patient (intraindividual) or in a given
population (interindividual). Generally, the
clinician focuses on intrapatient variability,
although interpatient variability is also significant and may render insights into processes
of care rather than individual therapeutic
processes.
For the anemia of chronic kidney disease
(CKD), variability may be defined by the
standard deviation or the coefficient of variation of the Hb for a single patient or population.3 Variability has also been evaluated by
the resident proportion of time outside stated
limits of Hb, and the term ‘‘rolling hemoglobin’’4 has often been used to characterize
this form of variability. An alternative description has been that of assessing the
change in consecutive Hb measurements

categorized as (1) all changes #0.5 g/dL, (2)
Hb decrease .0.5 g/dL, (3) Hb increase
.0.5 g/dL, and (4) both Hb decrease and increase .0.5 g/dL.5 More recently, variability,
particularly that referred to as ‘‘cycling’’ has
been characterized by the Hb amplitude, defined as the difference between the highest
and lowest Hb levels during a period of observation.6 Lastly, variability has been considered as ‘‘trajectory,’’ the first derivative or
slope/trajectory of Hb and time.7,8 In these
models, the Hb intercept defines the absolute
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Hb level, the Hb slope represents the change
of Hb levels over time, and the residual standard deviation (SD) represents the Hb variability.9,10
Importantly, Hb variability is a normal biological event, and a normal subject’s Hb may
vary by nearly 1 g/dL over the course of
a year.11,12 This is shown in Figure 1. The variation of Hb around a mean of 15.1 g/dL has
an SD of 0.6 g/dL. Lastly, the aforementioned
Hb variations are greater than those expected
from the accuracy of the measurement of Hb
for which the coefficient of variation is
,1.5% in dialysis patients3 and even less in
normal subjects.13
In CKD patients, one would expect even
greater variability than in healthy people
because of blood losses from frequent measurement, sampling errors and alterations of
extracellular fluid volume, and seasonal variation,14 and this is particularly true of patients
with minimal or no residual kidney function.15 Similar, systematic determinations of
‘‘normal’’ variability of Hb in CKD have not
been determined, stratified by CKD stage, or
validated by multiple observers. The only
available data suggest that variability is less
than that in end-stage renal disease (ESRD)
patients but greater than in healthy people.16
Moreover, the CKD patient is often subjected
to greater frequencies of Hb monitoring and
also to alterations of dosing of iron and/or
erythropoiesis-stimulating agents (ESAs).
Therefore, the ‘‘abnormal’’ Hb variability discussed in the literature is a convention that
cannot be directly compared against the ‘‘normal’’ variability of normal subjects. Nonetheless, it is the amplitudes of difference

Figure 1. Time-varying hemoglobin (Hb) levels
in a normal individual.

between CKD patients and normal individuals that the literature espouses as ‘‘variability.’’
Despite the artificiality of the term, variability remains significant, and determining
its cause in a CKD patient is a therapeutic
mandate, for it may be sentinel for adverse
events. This is usually true when the Hb trajectory or amplitude of variability is downward, but this is not always the case.
Conversely, upward amplitudes in Hb are
generally positively received but may be associated with unfavorable outcomes as well.
This review delineates Hb variability as a dynamic entity that is a function of multiple influences. Variability will be described within
the context of a broad range of intrapatient
and interpatient determinants that affect Hb,
including intrinsic and extrinsic forces. In addition, a mechanistic approach to elucidating
causation for erythropoietic hyporesponses
will be offered.

Hemoglobin: Values and Variability
Normal
The intra-assay coefficient of variation (CV) of
corpuscular Hb is about 5.5% to 8%,17-19 with
an SD of 1.8 to 2.7 g/dL. Given these relatively
small CVs for corpuscular Hb, the variability
of Hb among individuals and groups of
patients generally should not be attributed to
laboratory measurement in the absence of
flawed systematic quantitation error(s) or
specimen acquisition. Indeed, the CV for Hb
is generally low, approximately 0.68 to 0.82,
with SDs of 0.019 to 0.10.20
In large population studies such as
National Health and Nutrition Examination
Survey III and the Scripps-Kaiser Database,
blacks and whites have mean Hb levels ranging from 13 to 15 g/dL with an SD of 0.8 to
1.2 g/dL. White males experience a mild decile-dependent drop in Hb with age.21 In addition, Hb declines ‘‘normally’’ with aging by
a modest degree.22 Notably, analysis of the
Scripps-Kaiser data eliminated individuals
with iron deficiency (thresholds for exclusion:
transferrin saturation ,16% or serum ferritin
,10 g/L).
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Abnormal
Hemoglobin variability is greater in CKD patients and in older patients. Notably some of
the more elderly patients may not have been
recognized as having CKD because serum
creatinines were not transformed to estimated glomerular filtration rates.23 The CV
for Hb has a larger negative SD in whites
with a serum creatinine level .1.4 mg/dL
(124 mmol/L), C-reactive protein levels .1
mg/L, or erythrocyte sedimentation rate
levels .20 mm/hr.14 Namely, these individuals were more anemic with CKD and/or
inflammation. Correspondingly, in the analysis of an aging Netherlands cohort, much
greater degrees of anemia were positively associated with increased mortality.22 However, CRP levels were not reported in this
analysis.
The mortality association between worsening anemia and mortality has also been identified in several populations. In patients
hospitalized with acute myocardial infarction,
the frequency of death was inversely related to
the entry hematocrit (Hct), and an increasing
death rate followed the 30-day decline in
Hb.24 At Hct levels of 30% to 33%, the tangential slopes of the curvilinear relationship
between death and Hct decreased. Consequently, in a follow-up letter to this report,
the authors recommended that individual
Hct levels should be maintained at .33%
(Hb 11 g/dL) in patients experiencing acute
myocardial infarction.25 A similar relationship
was found between anemia and heart failure
in a meta-analysis.26 Anemia, and, hence, population-based variability, is also greater in
elderly blacks in comparison to whites and
correlates with mortality, impaired cognitive
function, and functional status.27 In this prospective, cohort study of 1,774 elderly male
and female community-dwelling participants
of the Duke Established Populations for Epidemiologic Studies of the Elderly, a component
of the National Institute on Aging study,
anemia was present in 24% of individuals using World Health Organization criteria. This
prevalence was significantly higher than those
of the 11.0% in males and 10.4% in females
that were reported in the noninstitutionalized
US population of the third National Health

85

and Nutrition Examination Survey (19881994).28
Taken collectively, lower Hb values are
related to CKD, aging, and cardiovascular disease events. Lower Hb values are significantly
associated with greater morbidity and mortality, particularly at Hb levels ,10 g/dL in
cardiovascular disease patients. Hb declines
with age from whichever cause, and CKD is
evident in some of these individuals. In
conclusion, because intraindividual Hb variability is a function of time-varying Hb, which
is unlikely to vary substantially at any single
point in time, the magnitude of the decrease
in Hb is the best predictor of adverse outcomes.

Hb Variability in CKD and Outcomes
The definition of Hb variability in CKD is itself
variable. In most cases, Hb variability is evaluated during a period of 3 to 6 months, using
nearly all Hb measurements available during
the specified interval. Because the frequency
of Hb monitoring varies from weekly to
monthly, generally, a sufficient number of
values are available to determine Hb variability in a particular patient.
The following definitions have been used in
the literature. Yang et al9 and Brunelli et a10
developed the following novel, linear regression-based metrics of Hb variability: intercept
defining an absolute Hb level, slope equating
to the change of time-varying Hb, and residual
SD representing variability. This group concluded that greater variability positively correlated with mortality as an independent risk
factor.
Lacson et al3 defined Hb level variability in
terms of 3-month rolling average Hb levels,
noting that this variability depended on interpatient variability. The SD of these averages
representing intrapatient variability was 1.2
g/dL, 0.3 g/dL greater than the general US
population. Twenty-eight percent of patients
with a rolling average Hb ,11 g/dL increased
their levels to .12 g/dL during 1 year of
observation. The investigators concluded
that Hb level variability was the result of multiple factors, including laboratory assays, biological influences, and individual therapeutic
responses to the treatment of anemia.
Standardized treatment algorithms were
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recommended as a measure to improve quality while reducing variability.
Regidor et al5 characterized the change in
consecutive Hb measurements in 4 ways during their retrospective analysis of nearly
40,000 maintenance hemodialysis patients:
(1) all changes #0.5 g/dL, (2) an Hb decrease
.0.5 g/dL, (3) an Hb increase .0.5g/dL, and
(4) both an Hb decrease and increase .0.5 g/dL.
After adjustment for time-varying confounders,
this group concluded that ESA dosing was beneficial from a survival standpoint. Lastly, the
authors correlated decreased survival with
a falling Hb that precipitated higher levels of
ESA dosing.
Hb variability has been defined in terms of
amplitude, the difference between the highest
and lowest Hb levels during the baseline
period. Fishbane and Berns6 identified the
principal components of recurrent cycling in
ESRD patients. These were ESA therapy that
was used to attain the target Hb and a narrow
target Hb range, which ironically induced frequent ESA dosing changes and ‘‘cycling.’’
Ebben et al29 classified ESRD patients into 6
groups in their 6-month study of Hb level fluctuations in ESRD patients receiving Medicare
with claims for epoetin alfa. Three groups
were classified based on Hb level: low (,11.0
g/dL), within target (11.0-12.5 g/dL), and
high ($12.5 g/dL). Subsequently, 6 groups
were defined as consistently low for 6 months,
consistently within target range, consistently
high, low-amplitude fluctuation with low
Hb, low-amplitude fluctuation with high Hb,
and high-amplitude fluctuation (HA; low,
target range, and high Hb). Just 10.3% of patients could maintain a stable Hb for the study
duration. The consistently low experienced
hospitalizations most frequently and had
the most comorbid illnesses. HA was the
most common pattern at 39.5%. In a later, similarly conducted study, the same group determined that Hb ,11 g/dL for .3 months,
rather than variability, was associated with
mortality.30

Determinants of Hb Variability and
a Suboptimal Response to ESA Therapy
Hb variability results from multiple sources.
When it is associated with declines of Hb, it

is frequently coupled with suboptimal
responses to ESA therapy (ie, monthly Hb
increases of ,0.5 g/dL). Etiologically, hyporesponses may be related to patient-related
factors, intercurrent events, and practice
pattern-related issues (Table 1). These hyporesponses may also be subdivided into 3 other
categories: blood loss, nonpathological, and
pathological. Blood loss produces a negative
trajectory of Hb over time. Nonpathological
causes of variability typically increase Hb
when evaluated in a time-varying fashion,
whereas pathological influences generally
induce Hb declines.
Blood loss occurs in multiple formats
including occult or overt gastrointestinal
blood loss from whichever cause, the annual
1 to 2 g of procedural blood losses in hemodialysis lines and filter,31 surgical interventions,
or hospitalizations with their associated multiple phlebotomy procedures. In a retrospective
review of 65 hemodialysis patients, Hb levels
were on average 0.7 g/dL lower 2 months
after discharge, despite an escalation of the
ESA dose of 45%.32 No effects of comorbid factors, including surgery or discharge diagnosis,
on Hb changes or epoetin alfa requirements
were detected. Patients transfused in hospital
had lower Hb levels and higher ESA doses
before and after hospitalization. Remarkably,
despite that hospitalization-associated blood
loss can be cut by nearly 75% simply by the
utilization of pediatric-sized tubes, this practice has never been adopted on a widespread
basis.33
Nonpathological causes of Hb variability
can be operationally defined as clinical circumstances that are unassociated with blood
loss or a specific disease entity or state. The
inadequate treatment of the anemia of CKD
by iron supplementation is chief among these.
Absolute or functional iron deficiency in
nondialysis (ND)-CKD and ESRD patients
renders ESA therapy suboptimal.34,35 The correction of iron deficiency characteristically reduces or maintains the preiron exposure ESA
dose and increases Hb.36-38 When iron therapy
does not correct anemia, an insufficient ESA
dose, blood loss, or a pathological cause of
Hb variability should be suspected.
Another reason for nonpathological Hb
variability is per protocol treatment of anemia.
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Table 1. Etiology of Suboptimal Response to ESA Therapy
Patient-Related Factors
ESA sensitivity

Intercurrent Events

Erythrocyte lifespan

Iron deficiency (absolute,
functional)
Infection(s): obvious, occult (AVG)

Parathyroid hormone level

Hospitalization (phlebotomy)

Inflammatory illness

Blood loss (bleeding,
hemolysis)
Pure red cell aplasia
Medications
Seasonal variation

Diabetes
Malignancy
Hematologic disease (hemolysis)

Malnutrition
Vitamin deficiency (B12, folate)

Practice Pattern-Related Issues
Inadequate protocol design
Facility- and provider-level protocol
adherence
Patient-level adherence (protocol,
medications)
Laboratory monitoring frequency
Narrow Hb target range
Dialysis adequacy, poor
Payment restrictions (ESRD MUE:
darbepoetin alfa 1,200 mcg/mo;
epoetin alfa 400,000 units/mo)

Inter-dialytic weight gain

Abbreviations: AVG, arteriovenous graft; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease;
MUE, medically unbelievable edit.

Essentially, in these circumstances, variability
is a function of process of care. Patients have
varying degrees of intrinsic, biological sensitivity to ESAs.39,40 Namely, small ESA dose
increments will produce a given positive
change of Hb in some, but the same incremental Hb change may require much larger ESA
doses in others (ie, ESA pseudoresistance).
Furthermore, others may show intermediate
levels of sensitivity to ESA. Given the differential ESA sensitivities of ESRD patients,
coupled with an inability to determine sensitivity a priori and the narrow constraint of
maintaining an idealized target Hb of 11 to
12 g/dL, the Hb can be highly variable at any
given time point in a particular individual.
However, when greater duration is permitted
to achieve the target, variability decreases.
Nonetheless, fewer than 50% of patients had
hemoglobin values within the 1.0 g/dL
National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (K-DOQI) recommended range in the retrospective, observational study (N ¼ 987) of Berns et al,4 despite
the use of a 6-month rolling Hb. At 1 month,
1 SD of Hb was 1.4 g/dL; at 3 months, 1 SD
was 1.1 g/dL; and at months 4 to 6, 1 SD
was 1.0 g/dL. In total, a 4.4-g/dL Hb spread
was required to encompass 90% of Hb values,
with the Hb range encompassing 50% and
80% of levels from a single month at 1.7
and 3.3 g/dL, respectively. The 6-year Hb

trend analysis of 65,009 patients by Lacson
et al3 corroborate those mentioned earlier.
Their analysis of the Fresenius Medical Care
North America database concluded that a 3month rolling Hb would exceed 12.5 g/dL
in 13% to 31% of facility-managed patients
given an expectation that 90% of Hb levels
were $10 g/dL.7 During 3 successive quarters of analysis, approximately 38% of patients were at the target Hb of 11 to 12 g/
dL, although many individuals moved above
and below the target. The ‘‘average individual patient’’ was predicted to experience an
Hb fluctuation of 1.4 g/dL. Lastly, the authors concluded that increasing the upper
bound of the target Hb range would lessen
Hb variability.
The correction of a deficiency of a critical
vitamin deficiency that imposes a state of
ineffective erythropoiesis should also be
considered among the causes of nonpathological causes of Hb variability. The adequate
repletion of vitamins B12 and/or folate in deficiency states may generate a brisk upward
slope of the Hb versus time curve, and
their assessment is recommended early on
during the investigation of anemia in CKD
patients.41,42 Another prominent cause of Hb
variability of nonpathological origin is suboptimal outpatient adherence to oral hematinic
therapy or, possibly, ESA dosing because
CKD/ESRD patients are susceptible to

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 22, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

88

Yee et al

medication-related problems and challenged
by the number of medications that they must
take,43,44 the estimates of which can be considered among the ‘‘unknown knowns.’’ ESRD
patients experience nonpathological Hb variations in both directions. These include the following: seasonal variations in Hb with peak
Hb values that were 0.6 g/dL higher in July8;
heterogeneous times of Hb assay, which may
occur after large or small interdialytic extracellular fluid volume changes; pregnancy45; pain
or anxiety during the venipuncture; geographic altitude of the hemodialysis unit
with hypoxia-driven erythropoiesis at greater
elevations; cigarette smoking; and patient
position.15
Pathological Hb variability deflects Hb
downward (ie, negative variability), excludes
nutritional deficiencies, aging, and bleeding,
and specifies that an alteration or change of
Hb stems from an abnormal condition that
inhibits optimal erythropoiesis. Such conditions are often of an inflammatory nature.
The etiologies are myriad and induce hyporesponsiveness to ESA therapy. Excluding the
intrinsic inflammation of ND-CKD and
ESRD, which includes increased concentrations of C-reactive protein, pernicious cytokines, hepcidin, and enhanced oxidative
stress-related markers, all of these states
impair erythropoiesis at various stages.46-49
Diabetic kidney disease, itself an inflammatory state,50 is associated with worse anemia
than those without diabetes.51,52 LiVecchi et
al52 examined 3 groups of patients: type 2 diabetics without CKD (n ¼ 75), type 2 diabetics
with CKD (n ¼ 106), and nondiabetic CKD
(n ¼ 100). Anemia was most frequent in diabetic kidney disease (70.5%) but also present
in diabetes alone (16%). In CKD stages 4 and
5, anemia prevalence was greater in diabetics
than in nondiabetics. Hence, it might be anticipated that diabetic kidney disease is associated with greater Hb variability than in
nondiabetic CKD individuals and attributable
to those factors that drive the anemia. Proteinuria has been posited as one of these factors
because erythropoietin losses are one consequence of albuminuria53 after observations in
the proteinuric rat, but this supposition has
not been rigorously tested, experimentally or
clinically.

Pathological variability resulting from
acquired infections is common. Hospitalizations occur 4 to 5 times more frequently in
CKD patients than in those without the diagnosis.54 Conceivably, the prolonged recovery
of Hb after infection-related hospitalization
is, in part, attributable to and exacerbated by
the inflammatory milieu incited by the infectious agent. Notwithstanding the obvious
infections incurred by hospitalized CKD
patients, occult infections from a variety of
sources should be ruled out (eg, abdominal
abscesses, infective endocarditis, and osteomyelitis). Included among these are nonfunctional arteriovenous grafts. These must be
suspected as a source bacterial infection in
iron-replete patients manifesting sluggish
responses after ESA exposure.55 The discovery
of this particular cause of ESA hyporesponsiveness has tremendous implications for
hemodialysis units with a large proportion of
nonfunctional grafts, from both patient care
and ESA utilization standpoints. Lastly,
inflammation from concomitant nonrenal diseases may provoke ESA resistance including
HIV/acquired immunodeficiency syndrome,
rheumatoid arthritis, lupus, and inflammatory
bowel disorders, among others.
Other pathological processes that impair
the net response to anemia therapy and negatively increase Hb variability can be categorized into 3 groups: bone marrow disorders
(fibrotic, infiltrative, inflammatory, and myelosuppressive), hemolysis, and acquired red
cell production disorders (lead and aluminum). Inflammatory marrow fibrosis from
secondary hyperparathyroidism of CKD has
been described by multiple observers. Nearly
2 decades ago, in a single-center experience
of 7 patients who required a mean epoetin
alfa dose of 174 U/kg to maintain an Hct of
35%, marrow fibrosis was correlated to the
extent of hyperparathyroidism.56 More recently, the original observation that hyperparathyroidism is associated with worse
anemia was confirmed.57 Myelophthisic disease from a myelodysplastic disorder or infiltration by malignancy may similarly impose
ESA hyporesponsiveness. A search for
a plasma cell dyscrasia must always be made
when the cause of CKD has not been established and anemia is disproportionate to the
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stage of CKD. Hemolytic anemia investigations should be prompted by failure to establish one of the usual suspects that induce
resistance to ESA and includes a thorough
review for medications that provoke hemolysis and for those that depress red cell production (eg, zidovudine and chemotherapeutic
agents). Abrupt, severe (.0.5 g/dL/wk)
declines in Hb after exposure to an ESA for
.4 weeks, with normal platelet and white
cell counts, may signal acquired pure red cell
aplasia,58 a neutralizing antibody disorder
primarily linked to the antigenicity of a nowdiscontinued epoetin formulation and leachates from the rubber stoppers of the vials
containing it. Lead exposure remains a scourge
of society,59,60 and chronic aluminum ingestion61,62 as phosphate-binder therapy is rare
today; however, the presence of either must
be ruled out when hyporesponsiveness to
ESA therapy is unresolved.

Reduction of Hemoglobin Variability in
Non–Dialysis-Dependent Chronic
Kidney Disease
Considering many of the reasons for variability, our group endeavored to offset variability
by developing an automated, algorithmic
approach to anemia management in our NDCKD population. Using 2 parallel treatment
algorithms that deliver oral or intravenous
iron and monthly subcutaneous darbepoetin
alfa, we have attempted to treat and maintain
nearly 600 patients to the KDOQI target. This
computerized program, the Computerized
Anemia-Management Program (CAMPÓ, version 3.0; Henry Ford Health System, Detroit,
MI), performs trend analysis of Hb, transferrin
saturation, and ferritin before calculating and
prescribing iron and ESA therapies (Fig 2).
Internal calculation of the slope of Hb versus
time, in 3-month intervals, prevents Hb from
rising too rapidly and from ‘‘overshooting.’’
By establishing monthly dosing limits,
futile attempts to treat hyporesponsive
patients are avoided and simple evaluation
of albumin levels may facilitate recognition
of these individuals.63 CAMP also stores
within its database procedural information
from the patient encounter including patient
vital signs, dose of iron and ESA adminis-
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tered, prescribing health care provider, and
site of administration. Any or all of the stored
parameters are queryable for application in
continuous quality improvement efforts. For
example, one could identify, analyze, and
print a report of those patients whose Hb
levels were ,10 g/dL, despite receipt of
.300 mg of monthly darbepoetin (Fig 3).
By using this approach, nearly 80% of
patients who adhered to the program for 5
months fell into the Hb range of 10.5 and
12.5 g/dL. More importantly, the 20% of
patients who fall outside of the target range
are identified. The most ESA-resistant and
most ESA-sensitive patients are generally
found within this group, and CAMP automatically generates ‘‘warnings’’ on these
patients that are e-mailed to respective health
care providers. Thus, although our results
show that the target Hb cannot be perfectly
struck as a ‘‘bull’s eye,’’ one may be close
and achieve clinically satisfactory results.
The latter is in accordance with the recently
updated KDOQI clinical practice guideline
statement 2.1.141 that permits individualized
therapy for the asymptomatic patient who is
‘‘doing well’’ at an Hb that is ,11 g/dL. In
this instance, further treatment is not absolutely required, and CAMP automatically
determines the treatment strategy for such individuals and informs the health care provider of its decision who may choose to
override the decision based on the clinical
context. The integration of ‘‘softer’’ boundaries essentially melds into our algorithm
the prior information of Lacson et al3 and
Berns et al4 that describes the implausibility
that all patients can be treated to a narrow 1
g/dL Hb range and prevents clinically
unnecessary Hb cycling.

Conclusions
Hb variability is an inherent phenomenon of
man in both health and disease. It must be
anticipated during the treatment of anemia
in CKD. Hb variability is neither inherently
bad or good, but an integrated response of
the patient, which reflects a composite of
iron availability to the erythron, ESA dose,
and erythropoietic responsiveness/sensitivity
and the multiple external forces that may
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Figure 2. Computerized Anemia Management Program (CAMPÓ) algorithms for iron and darbepoetin
therapy in chronic kidney disease. Hb, hemoglobin; TSAT, transferrin saturation; DA, darbepoetin alpha.

inhibit it. Relaxation of Hb target ranges prevents protocol-driven swings in variability
and conforms to current clinical guidelines
and recommendations. The imprecision of

the term ‘‘variability’’ has been ‘‘much ado
about nothing.’’ However, persistently negative variability and ultrahigh ESA dosing to
attain a Hb target and preclude downward

Figure 3. Sample query of chronic kidney disease (CKD) patients receiving 300 mg or more of darbepoetin with a hemoglobin concentration of 10 g/dL or less and from Computerized Anemia Management
Program (CAMPÓ).
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cycling are ‘‘much ado about something’’64
and contrasts the situation in which greater
ESA responsiveness is associated with a survival benefit.65 We posit that anemia management protocolization and operationalization
can create Hb stability and quality performance at the individual and facility levels,
and protocols should target those patients
who require it the most.
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